Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash, cash equivalents and restricted cash	$ 58,215	$ 110,891
Available-for-sale securities, at fair value	162,064	292,735
Prepaid expenses	10,516	8,813
Other current assets	7,104	7,082
Total current assets	237,899	419,521
Property, plant and equipment, net	333,411	290,262
Intangible assets, net	9,837	10,262
Right-of-use assets	44,907	45,297
Other assets	232	210
Total Assets	626,286	765,552
Current liabilities:
Accounts payable	4,460	35,866
Accrued expenses	46,604	39,763
Accrued payroll and benefits	8,777	17,963
Lease liabilities	3,421	10,563
Deferred revenue	0	866
Other liabilities	461	435
Total current liabilities	63,723	105,456
Long-term liabilities:
Lease liabilities, net of current portion	115,157	104,608
Liability related to the sale of future royalties	273,692	268,326
Total long-term liabilities	388,849	372,934
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,500 and 107,312 shares	200	200
Additional paid-in capital	1,320,356	1,300,395
Accumulated other comprehensive loss	(1,255)	(3,222)
Accumulated deficit	(1,158,894)	(1,026,030)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	160,407	271,343
Noncontrolling interest	13,307	15,819
Total noncontrolling interest and stockholders’ equity	173,714	287,162
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 626,286	$ 765,552